Altogen/MG-63 Transfection Kit (Osteosarcoma, CRL-1427)/1.5 ml CRISPR(Catalog #2173)

Description

ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).

Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).

TransfectionReagentforMG-63Cells(OsteosarcomaCells,CRL-1427)

• Twocomponentformulationenhanceslipidmediatedtransfectionefficiency
• Optimizedeasy-to-usetransfectionprotocolprovidedfortransfectionofsiRNA,DNA,mRNA,andmicroRNA
• Hightransfectionefficacyinthe presenceofserum
• ExpandyourRNAiapplicationwithareagentoptimizedfordeliveryofbothsiRNAandplasmid
• ReproducIBLetransfectionresults
• Workswellforstandardreversetransfectionandhigh-throughputapplications
• DownloadinvitroMG63 transfectionprotocol:[PDF]
• Download MG63CRISPR/Cas9transfectionprotocol:[PDF]
• DownloadPowerPointpresentationforNIH3T3 transfectionkit:[PPT]
• DevelopedandmanufacturedbyAltogenBiosystems

TransfectionEfficiency:

Reagentexhibitsatleast77%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.

TransfectionProtocolandMSDS:

DownloadAltogenBiosystemsMG-63TransfectionProtocol:[PDF]

DownloadMSDS:[PDF]

MG-63CellLine:

Sarcomaisacancerofbonesandconnectivetissuesthatisquiterareinadults.However,itcomprisesapproximately20%ofallchildhoodcancers,asindicatedbytheSarcomaFoundationofAmerica(SFA).Humancelllinesarevaluablepreclinicalmodelsforsarcomaresearchaswellasforevaluationoftheefficacyortoxicityofpotentialdrugcandidates.TheMG-63celllinewasestablishedfromthebonetissueofa14-year-oldCaucasianmalewithosteosarcoma.Thiscelllineexhibitsfibroblastmorphologyandshowshighlevelsofinterferonproductionwheninducedbycycloheximide,actinomycinD,andpolyinosinic-polycytidylicacid.TheseMG-63cellsexpressTGF-betaRIandTGF-betaRIIreceptorsandcouldbeusefulasatransfectionhostindifferenttypesofbiomedicalresearchapplications.TheMG-63celllineishypotriploidwithamodalchromosomenumberof66.AltogenBiosystemsprovideshigh-efficiencytransfectionreagentkitsfortheMG-63osteosarcomacellline.

Data:

Figure1.siRNAstargetingLaminA/CmRNAornon-silencingcontrolsiRNAweretransfectedintoMG63cellsfollowingtherecommendedprotocol.At48hourspost-transfectionthecellswereanalyzedbyqRT-PCRforLaminA/Cgeneexpressionlevels.18SrRNAlevelswereusedtonormalizetheLaminA/Cdata.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=4).

Figure2.ProteinexpressionofLaminAinMG-63cells.DNAplasmidexpressingLaminAorsiRNAtargetingLaminAweretransfectedintoMG-63cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.

MG63TransfectionReagentcitationreferences:

• DataBrief.2016Jun;7:177–182.Datasupportingattemptedcaveolae-mediatedphagocytosisofsurface-fixedmicro-pillarsbyhumanosteoblasts.Moerkeetal[PDF]

AltogenBiosystems:
AltogenBiosystemsprovidespre-optimizedtransfectionkitsandelectroporationproductsforlifescienceresearch.Transfectionproductsaredevelopedforindividualcancercelllineandtransfectionprotocolsareoptimizedtoenablehightransfection efficiencyofbiomolecules.AltogenBiosystemsdevelopedinvivodeliveryproductsforsmallanimalresearch,mouseandrattargetedtissuedelivery:livertargeted,pancreastargeted,kidneytargeted,PEG-Liposome-,Nanoparticle-,Lipid-,andPolymer-basedinvivotransfectionkits.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofbiomolecules.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.

AltogenLabsResearchServices:

AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).

VolumeOptions:

• 0.5ml(Catalog#6848)
• 1.5ml(Catalog#6849)
• 1.5mlCRISPR(Catalog#2173)
• 8.0ml(Catalog#7063)